Skip to main content


Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Fig. 4 | BMC Cancer

Fig. 4

From: Combination of lutetium-177 labelled anti-L1CAM antibody chCE7 with the clinically relevant protein kinase inhibitor MK1775: a novel combination against human ovarian carcinoma

Fig. 4

Fluorescence microscopy of γH2A.X. IGROV1 cells were incubated with 2.5 MBq 177Lu-DOTA-chCE7 for 4 h or with 100 nM MK1775 for 48 h. For combination, cells were simultaneously incubated with both agents. After 4 h incubation, 177Lu-DOTA-chCE7 was removed and MK1775 was further incubated until 48 h were reached. Cells were fixed and stained and γH2A.X foci were counted and cells grouped depending on (a) no observed (b) ≤ 5 (c) ≥ 6 or (d) non-distinguishable γH2A.X foci (intensively positive). a-d shows examples of IGROV1 cells with accordant numbers of γH2A.X foci. (e) summarizes all γH2A.X positive cells expressed in percent of total cell numbers counted

Back to article page